23andMe Launches TV Ad Campaign For DTC Gene Testing Service While Seeking 510(k)
This article was originally published in The Gray Sheet
Executive Summary
The seller of a $99 direct-to-consumer genetic test service is running ads with actors discussing the values of learning one’s personal DNA profile. But the firm’s continued marketing of the testing services and now its high-profile ads may raise questions about the regulatory status of its offerings.
You may also be interested in...
FDA, 23andMe Open Up Market Pathway For DTC Genetics
The Google-backed firm's carrier screening assay for a rare disease called Bloom syndrome is the first DTC genetic test to achieve sign off from FDA. More importantly, the marketing authority was awarded in a manner that could significantly streamline the path to market for future DTC carrier-screening assays.
FDA, 23andMe Open Up Market Pathway For DTC Genetics
The Google-backed firm's carrier screening assay for a rare disease called Bloom syndrome is the first DTC genetic test to achieve sign off from FDA. More importantly, the marketing authority was awarded in a manner that could significantly streamline the path to market for future DTC carrier-screening assays.
Lawmakers Want HIPAA Data Access Rules Amended To Encourage Consumer ‘Shopping’ For Diagnostics
Lawmakers at a House hearing discussed amending the HIPAA privacy regulations to allow patients more access to their own data, and to encourage patient participation in selecting their own genetic tests, mammograms or other diagnostics.